Insider Selling: Guardant Health (NASDAQ:GH) Director Sells $130,060.00 in Stock

Guardant Health, Inc. (NASDAQ:GH) Director Medina Manuel Hidalgo sold 1,000 shares of the company’s stock in a transaction dated Thursday, May 28th. The stock was sold at an average price of $130.06, for a total transaction of $130,060.00. Following the completion of the sale, the director directly owned 639 shares of the company’s stock, valued at $83,108.34. The trade was a 61.01% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Medina Manuel Hidalgo also recently made the following trade(s):

• On Wednesday, May 20th, Medina Manuel Hidalgo sold 1,250 shares of Guardant Health stock. The stock was sold at an average price of $107.09, for a total transaction of $133,862.50.
• On Friday, March 6th, Medina Manuel Hidalgo sold 1,300 shares of Guardant Health stock. The stock was sold at an average price of $91.54, for a total transaction of $119,002.00.

Guardant Health Price Performance

GH stock opened at $129.69 on Monday. The company has a market capitalization of $17.20 billion, a P/E ratio of -38.26 and a beta of 1.61. The company has a 50-day simple moving average of $95.08 and a 200 day simple moving average of $99.96. Guardant Health, Inc. has a fifty-two week low of $38.03 and a fifty-two week high of $133.97.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on GH shares. Canaccord Genuity Group boosted their price target on shares of Guardant Health from $125.00 to $135.00 and gave the stock a “buy” rating in a research report on Friday, February 20th. BTIG Research set a $160.00 price target on shares of Guardant Health and gave the stock a “buy” rating in a research report on Wednesday. Robert W. Baird started coverage on shares of Guardant Health in a research report on Tuesday, February 17th. They issued an “outperform” rating and a $120.00 price target on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Guardant Health in a research report on Tuesday, April 21st. Finally, Guggenheim cut shares of Guardant Health from a “buy” rating to a “buy” rating in a research report on Thursday. Nineteen analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Guardant Health presently has a consensus rating of “Moderate Buy” and an average price target of $129.79.

Institutional Trading of Guardant Health

Several institutional investors and hedge funds have recently bought and sold shares of GH. Knights of Columbus Asset Advisors LLC acquired a new position in shares of Guardant Health in the 3rd quarter valued at about $1,554,000. Erste Asset Management GmbH increased its holdings in shares of Guardant Health by 10.4% in the 3rd quarter. Erste Asset Management GmbH now owns 705,217 shares of the company’s stock valued at $43,716,000 after purchasing an additional 66,617 shares during the period. Segall Bryant & Hamill LLC increased its holdings in shares of Guardant Health by 57.8% in the 3rd quarter. Segall Bryant & Hamill LLC now owns 305,147 shares of the company’s stock valued at $19,066,000 after purchasing an additional 111,822 shares during the period. TD Asset Management Inc increased its holdings in shares of Guardant Health by 16.1% in the 3rd quarter. TD Asset Management Inc now owns 188,810 shares of the company’s stock valued at $11,797,000 after purchasing an additional 26,210 shares during the period. Finally, GSA Capital Partners LLP increased its holdings in shares of Guardant Health by 155.5% in the 3rd quarter. GSA Capital Partners LLP now owns 21,982 shares of the company’s stock valued at $1,373,000 after purchasing an additional 13,378 shares during the period. Institutional investors and hedge funds own 92.60% of the company’s stock.

About Guardant Health

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.